How artificial intelligence can change the pharmaceutical landscape
09 October 2019
LAC Lugano Arte e Cultura
Artificial Intelligence (AI) is gaining more and more importance in the pharmaceutical sector, deeply transforming the drug discovery process. There are many potential benefits of applying AI techniques to improve the development of new molecules and the identification of new targets, cutting R&D costs and time.

In drug discovery, AI helps in predicting the efficacy and safety of molecules. It gives researchers a much broader chemical pallet for the selection of the best molecules for drug testing and delivery. In this context, drug repurposing is another important area where AI can have a substantial impact. With the extensive amount of clinical and pharmaceutical data available to date, AI algorithms find suitable drugs that can be repurposed for an alternative use in medicine.

Moreover, with the help of AI, it becomes easier to run clinical tests, diagnose diseases and provide the most effective treatment for a particular disease. As it can interpret test results, AI can also look through various sources including publications to correctly diagnose critical ailments.

New approaches based on AI in the drug discovery process and in the repositioning of old molecules will be presented during this particular Forum. We hope to provide an overview of the sectors where AI might have an impact on the pharmaceutical pipeline and play a crucial role in the pharmaceutical world in the coming years.

The Forum is organized by IBSA Foundation in collaboration with Andrea Danani (Istituto Dalle Molle di studi sull’intelligenza artificiale-IDSIA, USI e SUPSI).

The Forum will be held in English. The entrance is free, with mandatory registration.

The speakers

  • Juergen Schmidhuber, NNAISENSE Lugano, Switzerland; Swiss AI Lab IDSIA, Manno, Switzerland; USI & SUPSI, Lugano, Switzerland
  • Ed Griffin, MedChemica Ltd., Biohub, Alderley Park, Macclesfield, Cheshire, United Kingdom
  • Gianni De Fabritiis, ICREA, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; Acellera, Barcelona, Spain
  • Sean Ekins, Collaborations Pharmaceuticals, Inc., Raleigh, United States of America; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States of America
  • Alex Zhavoronkov, Insilico Medicine, Hong Kong; Buck Institute for Research on Aging, Novato, United States of America; Biogerontology Research Foundation, London, United Kingdom
  • Alessandro Curioni, IBM Research Lab, Zurich, Switzerland; Swiss Academy of Engineering Sciences, Zurich, Switzerland